Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline Review, H1 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline Review, H1 2015', provides an overview of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Clostridium Difficile Infections (Clostridium Difficile Associated Disease)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 8

Global Markets Direct Report Coverage 8

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview 9

Therapeutics Development 10

Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Overview 10

Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Comparative Analysis 11

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Therapeutics under Development by Companies 12

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Therapeutics under Investigation by Universities/Institutes 17

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Products under Development by Companies 21

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Products under Investigation by Universities/Institutes 25

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Companies Involved in Therapeutics Development 26

Absynth Biologics Limited 26

Actelion Ltd 27

ActogeniX NV 28

Adenium Biotech ApS 29

AIMM Therapeutics B.V. 30

Akthelia pharmaceuticals ehf 31

AmpliPhi Biosciences Corporation 32

Assembly Biosciences, Inc. 33

AvidBiotics Corp. 34

C3 Jian, Inc 35

Daiichi Sankyo Company, Limited 36

Evec, Inc. 37

GangaGen Inc. 38

ImmunoBiology Ltd. 39

Immuron Limited 40

Inovio Pharmaceuticals, Inc. 41

MedImmune, LLC 42

Merck & Co., Inc. 43

MGB Biopharma Limited 44

Microbiotix, Inc. 45

Micropharm Ltd 46

Nanotherapeutics, Inc. 47

Novabiotics Ltd 48

Oragenics, Inc. 49

Pfizer Inc. 50

Procarta Biosystems Ltd 51

Prokarium Ltd. 52

Sanofi Pasteur SA 53

Sarum Biosciences Limited 54

Sequella, Inc. 55

Shire Plc 56

Sorrento Therapeutics, Inc. 57

Stellar Biotechnologies, Inc. 58

Summit Therapeutics plc. 59

Synthetic Biologics, Inc. 60

Valneva SE 61

VaxInnate Corporation 62

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Therapeutics Assessment 63

Assessment by Monotherapy Products 63

Assessment by Combination Products 64

Assessment by Target 65

Assessment by Mechanism of Action 67

Assessment by Route of Administration 69

Assessment by Molecule Type 71

Drug Profiles 73

(actoxumab + bezlotoxumab)-Drug Profile 73

actoxumab-Drug Profile 74

AKT-10081-Drug Profile 75

AmpliPHAGE-004-Drug Profile 76

Antibodies for Enterocolitis-Drug Profile 77

AP-114-Drug Profile 78

bezlotoxumab-Drug Profile 79

Biologic for Clostridium Difficile Enteropathy-Drug Profile 80

Biologic for Clostridium difficile Infections-Drug Profile 81

cadazolid-Drug Profile 82

Cdiff snare-Drug Profile 83

clostridium difficile vaccine-Drug Profile 84

Clostridium difficile vaccine-Drug Profile 85

clostridium difficile vaccine-Drug Profile 86

Clostridium difficile vaccine-Drug Profile 87

clostridium difficile vaccine-Drug Profile 88

Clostridium difficile vaccine-Drug Profile 89

Clostridium difficile vaccine-Drug Profile 90

Clostridium difficile vaccine-Drug Profile 92

clostridium difficile vaccine-Drug Profile 93

CRS-3123-Drug Profile 94

Drug for Clostridium difficile Infection-Drug Profile 95

Endolysin-Drug Profile 96

EV-029104-Drug Profile 98

EV-029105A-Drug Profile 99

fidaxomicin-Drug Profile 100

GBV-003-Drug Profile 103

GBV-006-Drug Profile 104

GN snare-Drug Profile 105

IMM-529-Drug Profile 106

INS-001-Drug Profile 107

INX-201-Drug Profile 108

MB-101-Drug Profile 109

MBX-500-Drug Profile 110

MGBBP-3-Drug Profile 111

Monoclonal Antibodies for Clostridium difficile-Drug Profile 113

Monoclonal Antibody for Clostridium Difficile Infections-Drug Profile 114

Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections-Drug Profile 115

Monoclonal Antibody to Inhibit Toxin A for Clostridium Difficile Infections-Drug Profile 116

MU-1140-Drug Profile 117

NP-432-Drug Profile 119

OraCAb-Drug Profile 120

P-4A-Drug Profile 121

PF-06425090-Drug Profile 122

PolyCAb-Drug Profile 123

PRO-391-Drug Profile 124

ramoplanin-Drug Profile 125

RBX-2660-Drug Profile 126

Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections-Drug Profile 127

SER-109-Drug Profile 128

SER-262-Drug Profile 129

Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections-Drug Profile 130

Small Molecules for Clostridium Difficile Infections-Drug Profile 131

Small Molecules to Inhibit DNA Synthesis for Infectious Diseases-Drug Profile 132

Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections-Drug Profile 134

SMT-19969-Drug Profile 135

SMT-21829-Drug Profile 137

SQ-109-Drug Profile 138

SQ-641-Drug Profile 141

surotomycin-Drug Profile 142

SYN-004-Drug Profile 143

Synthetic Peptide for Clostridium difficile Infections-Drug Profile 144

VAL-301-Drug Profile 145

VLA-84-Drug Profile 147

VP-20621-Drug Profile 149

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Recent Pipeline Updates 150

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Dormant Projects 177

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Discontinued Products 179

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Product Development Milestones 180

Featured News & Press Releases 180

Appendix 189

Methodology 189

Coverage 189

Secondary Research 189

Primary Research 189

Expert Panel Validation 189

Contact Us 189

Disclaimer 190

List of Tables

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H1 2015 14

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Development by Companies, H1 2015 (Contd..3) 20

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Late Stage Development, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Development, H1 2015 24

Products under Development by Companies, H1 2015 25

Products under Development by Companies, H1 2015 (Contd..1) 26

Products under Development by Companies, H1 2015 (Contd..2) 27

Products under Development by Companies, H1 2015 (Contd..3) 28

Products under Investigation by Universities/Institutes, H1 2015 29

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Absynth Biologics Limited, H1 2015 30

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Actelion Ltd, H1 2015 31

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by ActogeniX NV, H1 2015 32

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Adenium Biotech ApS, H1 2015 33

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by AIMM Therapeutics B.V., H1 2015 34

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Akthelia pharmaceuticals ehf, H1 2015 35

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by AmpliPhi Biosciences Corporation, H1 2015 36

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Assembly Biosciences, Inc., H1 2015 37

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by AvidBiotics Corp., H1 2015 38

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by C3 Jian, Inc, H1 2015 39

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 40

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Evec, Inc., H1 2015 41

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by GangaGen Inc., H1 2015 42

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by ImmunoBiology Ltd., H1 2015 43

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Immuron Limited, H1 2015 44

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 45

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by MedImmune, LLC, H1 2015 46

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Merck & Co., Inc., H1 2015 47

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by MGB Biopharma Limited, H1 2015 48

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Microbiotix, Inc., H1 2015 49

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Micropharm Ltd, H1 2015 50

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Nanotherapeutics, Inc., H1 2015 51

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Novabiotics Ltd, H1 2015 52

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Oragenics, Inc., H1 2015 53

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Pfizer Inc., H1 2015 54

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Procarta Biosystems Ltd, H1 2015 55

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Prokarium Ltd., H1 2015 56

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Sanofi Pasteur SA, H1 2015 57

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Sarum Biosciences Limited, H1 2015 58

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Sequella, Inc., H1 2015 59

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Shire Plc, H1 2015 60

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Sorrento Therapeutics, Inc., H1 2015 61

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Stellar Biotechnologies, Inc., H1 2015 62

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Summit Therapeutics plc., H1 2015 63

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Synthetic Biologics, Inc., H1 2015 64

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Valneva SE, H1 2015 65

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by VaxInnate Corporation, H1 2015 66

Assessment by Monotherapy Products, H1 2015 67

Assessment by Combination Products, H1 2015 68

Number of Products by Stage and Target, H1 2015 70

Number of Products by Stage and Mechanism of Action, H1 2015 72

Number of Products by Stage and Route of Administration, H1 2015 74

Number of Products by Stage and Molecule Type, H1 2015 76

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics-Recent Pipeline Updates, H1 2015 154

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Dormant Projects, H1 2015 181

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Dormant Projects (Contd..1), H1 2015 182

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Discontinued Products, H1 2015 183

List of Figures

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H1 2015 14

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Products, H1 2015 24

Assessment by Monotherapy Products, H1 2015 67

Number of Products by Top 10 Targets, H1 2015 69

Number of Products by Stage and Top 10 Targets, H1 2015 70

Number of Products by Top 10 Mechanism of Actions, H1 2015 71

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 72

Number of Products by Top 10 Routes of Administration, H1 2015 73

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 74

Number of Products by Top 10 Molecule Types, H1 2015 75

Number of Products by Stage and Top 10 Molecule Types, H1 2015 76

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Absynth Biologics Limited

Actelion Ltd

ActogeniX NV

Adenium Biotech ApS

AIMM Therapeutics B.V.

Akthelia pharmaceuticals ehf

AmpliPhi Biosciences Corporation

Assembly Biosciences, Inc.

AvidBiotics Corp.

C3 Jian, Inc

Daiichi Sankyo Company, Limited

Evec, Inc.

GangaGen Inc.

ImmunoBiology Ltd.

Immuron Limited

Inovio Pharmaceuticals, Inc.

MedImmune, LLC

Merck & Co., Inc.

MGB Biopharma Limited

Microbiotix, Inc.

Micropharm Ltd

Nanotherapeutics, Inc.

Novabiotics Ltd

Oragenics, Inc.

Pfizer Inc.

Procarta Biosystems Ltd

Prokarium Ltd.

Sanofi Pasteur SA

Sarum Biosciences Limited

Sequella, Inc.

Shire Plc

Sorrento Therapeutics, Inc.

Stellar Biotechnologies, Inc.

Summit Therapeutics plc.

Synthetic Biologics, Inc.

Valneva SE

VaxInnate Corporation

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutic Products under Development, Key Players in Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Pipeline Overview, Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Pipeline, Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com